CN-119679774-B - Medicine for preventing or treating metabolic diseases and application thereof

Abstract

The invention relates to a medicament for preventing or treating metabolic diseases and application thereof, and relates to the technical field of biological medicines, and application of N-acetylvaline in preparation of products for treating or preventing metabolic diseases. The invention provides a novel metabolic regulation drug, functional food or nutritional supplement based on N-acetylvaline, which is applied to the prevention and treatment of obesity and metabolic diseases. N-acetylvaline can maintain energy balance by regulating energy intake and energy consumption, so as to effectively prevent and treat obesity and related diseases. N-acetylvaline is taken as a movement-induced metabolite and has a dual regulation mechanism, namely, on one hand, energy intake is regulated, on the other hand, energy consumption is promoted, so that lasting metabolic regulation is realized in a physiological environment, the N-acetylvaline has long in-vivo action time, small side effect and remarkable lipid-reducing effect.

Inventors

• SHI LIJUN
• Wu baile
• ZHANG YANYAN

Assignees

• 北京体育大学

Dates

Publication Date

20260508

Application Date

20241115

Claims (6)

1. Use of n-acetylvaline as sole active ingredient for the preparation of a product for the treatment or prophylaxis of metabolic diseases, characterized in that the metabolic diseases are obesity or diabetes.
2. 2. The use according to claim 1, wherein the product is a medicament.
3. 3. The use according to claim 2, wherein the medicament further comprises a pharmaceutically acceptable adjuvant.
4. 4. The use according to claim 2, wherein the pharmaceutical dosage form comprises at least one of an injection, an oral tablet, an oral capsule, an oral liquid formulation.
5. 5. The use according to claim 2, wherein when the medicament is in the form of an injection, the medicament further comprises dimethyl sulfoxide, polysorbate and physiological saline.
6. 6. The use according to claim 5, wherein the volume ratio of dimethyl sulfoxide, polysorbate and physiological saline is 1:1:8.

Description

Medicine for preventing or treating metabolic diseases and application thereof Technical Field The invention relates to the technical field of biological medicines, in particular to a medicine for preventing or treating metabolic diseases and application thereof. Background Metabolic diseases such as obesity and type 2 diabetes have become a global increasingly serious public health problem, the root cause of which is a long-term imbalance in energy intake and consumption. Traditional methods of treatment include medications, surgical interventions, and lifestyle changes by adjusting diet and exercise habits. Although these methods can alleviate symptoms to some extent, there are general problems of non-sustained efficacy, significant side effects, and poor patient compliance. In recent years, scientific research has revealed a profound role for exercise in regulating metabolic health. Exercise not only improves muscle and cardiovascular function, but also maintains energy balance by promoting the production of various metabolites. These metabolites, collectively referred to as "exercise factors" or "exerkines", play an important role in regulating appetite, promoting energy expenditure, and improving overall metabolic health. In view of the above, the present invention provides a medicament for preventing or treating metabolic diseases and use thereof. Disclosure of Invention The invention aims to provide a medicine for preventing or treating metabolic diseases and application thereof. The purpose is to provide a newly discovered exercise factor N-acetylvaline. The technical scheme for solving the technical problems is as follows: In a first aspect, the use of N-acetylvaline for the preparation of a product for the treatment or prophylaxis of metabolic disorders. Wherein the structure of N-acetylvaline is as follows:。 further, the metabolic disease includes obesity, diabetes or metabolic syndrome. Further, the product includes a medicament. In a second aspect, a medicament for treating or preventing a metabolic disorder, the medicament comprising the N-acetylvaline. Further, the medicine also comprises medicinal auxiliary materials and/or carriers. Further, the dosage form of the medicine comprises at least one of injection, oral tablet, oral capsule and oral liquid preparation. Further, when the dosage form of the drug is an injection, the drug further includes dimethyl sulfoxide (DMSO), kolliphore (polysorbate), and physiological saline. Wherein dimethyl sulfoxide is used as a main solvent to increase the solubility of N-acetylvaline, polysorbate is used as an auxiliary agent, and physiological saline provides physiological compatibility, so that the compound can be effectively absorbed after in vivo injection. Further, the volume ratio of the dimethyl sulfoxide, the polysorbate and the physiological saline is 1:1:8, so as to form a solvent system. The preparation method of the injection comprises the steps of dissolving commercially available N-acetylvaline in the solvent system according to a proportion, and carrying out the dissolving process at room temperature, wherein gentle stirring is needed until the solution is completely dissolved, so as to obtain a stable solution. The invention newly discovers an N-acetylvaline (N-ACETYLVALINE, NAV) exercise factor, and experimental results show that the concentration of the N-acetylvaline in blood after exercise is obviously increased, the energy balance can be maintained by simultaneously regulating the dual mechanism of energy intake and consumption, and the N-acetylvaline has great application potential in preventing and treating metabolic diseases as a exercise-induced metabolism regulator although the specific action mechanism of the N-acetylvaline is not completely elucidated yet. The invention provides a novel metabolic regulation medicament, functional food or nutritional supplement based on N-acetylvaline, which is applied to the prevention and treatment of obesity and metabolic diseases, wherein the N-acetylvaline maintains energy balance by regulating energy intake and energy consumption, so that the obesity and related diseases (such as type 2 diabetes) can be effectively prevented and treated. N-acetylvaline is taken as a movement-induced metabolite and has a dual regulation mechanism, namely, on one hand, energy intake is regulated, on the other hand, energy consumption is promoted, so that lasting metabolic regulation is realized in a physiological environment, the N-acetylvaline has long in-vivo action time, small side effect and remarkable lipid-reducing effect. The beneficial effects of the invention are as follows: (1) The invention realizes lasting and obvious weight reduction effect through the double-effect mechanism, and avoids the problem of short treatment effect of the traditional medicine, unlike the traditional medicine which aims at only a single mechanism (such as appetite suppression or energy consumption increase). (2) The ex